Navigation Links
Tanespimycin in Medical News
Kosan Opens TIME-1 Pivotal Phase 3 Trial in Multiple Myeloma
...rporated (Nasdaq: KOSN ) today announced that the tanespimycin in Myeloma Evaluation or TIME-1 pivotal Phase 3 trial for tanespimycin as a potential treatment for multiple myeloma is o...lment. TIME-1 is a pivotal Phase 3 trial comparing tanespimycin in combination with bortezomib (Velcade(R)) with b...Tanespimycin in Medical Technology
Tanespimycin is the First Hsp90 Inhibitor to Enter Registration Trials
HAYWARD, Calif., Sept. 6 /PRNewswire-FirstCall/ -- Kosan Biosciences
Incorporated (Nasdaq: KOSN ) today announced that it has successfully
reached a binding agreement with the U.S. Food and Drug Administration
(FDA) on th...
HAYWARD, Calif., June 04, 2007 /PRNewswire-FirstCall/ -- Kosan Biosciences Incorporated presented preliminary data from a Phase 2 monotherapy trial showing that tanespimycin demonstrated antitumor activity and tolerability in patients with metastatic melanoma, including one patient with a BRAF mut...
...ster titled, "Phase 2 trial of the Hsp90 inhibitor tanespimycin (Tan) + trastuzumab (T) in patients (pts) with HER...L. "The response data from this Phase 2 trial of tanespimycin plus trastuzumab have grown stronger as more patie...ve been treated, underscoring our observation that tanespimycin is a highly active and tolerable agent in patients...
...rvival. Tanespimycin (KOS-953) is being tested in combination with bortezomib in patients with multiple myeloma in a registration program called TIME. tanespimycin is also being studied in HER2-positive metastatic breast cancer in combination with Herceptin, and as monotherapy in metastatic melanoma. Intravenous ...
HAYWARD, Calif., June 04, 2007 /PRNewswire-FirstCall/ -- Kosan Biosciences Incorporated presented preliminary data from a Phase 2 monotherapy trial showing that tanespimycin demonstrated antitumor activity and tolerability in patients with metastatic melanoma, including one patient with a BRAF mut...
...ster titled, "Phase 2 trial of the Hsp90 inhibitor tanespimycin (Tan) + trastuzumab (T) in patients (pts) with HER...L. "The response data from this Phase 2 trial of tanespimycin plus trastuzumab have grown stronger as more patie...ve been treated, underscoring our observation that tanespimycin is a highly active and tolerable agent in patients...
Kosan Announces Data Presentations at ASCO 2008 Annual Meeting
...on targeting multiple pathways involved in cancer cell growth and survival. tanespimycin (KOS-953) is being tested in combination with Velcade(R) (bortezomib) in patients with multiple myeloma in a clinical program called TIME. tanespimycin is also being studied in HER2-positive metastatic breast cancer in combinat...Kosan Presents Preclinical Data on Nuclear Export Inhibitors, Novel Anticancer Agents, at AACR
...on targeting multiple pathways involved in cancer cell growth and survival. tanespimycin (KOS-953) is being tested in combination with Velcade(R) (bortezomib) in patients with multiple myeloma in a clinical program called TIME. tanespimycin is also being studied in HER2-positive metastatic breast cancer in combinat...Kosan Initiates Phase 2 Trial of Epothilone KOS-1584 in Non-Small Cell Lung Cancer
...on targeting multiple pathways involved in cancer cell growth and survival. tanespimycin (KOS-953) is being tested in combination with Velcade(R) (bortezomib) in patients with multiple myeloma in a clinical program called TIME. tanespimycin is also being studied in HER2-positive metastatic breast cancer in combinat...Kosan Presents Updated Data on Hsp90 Inhibitor, Tanespimycin, in Multiple Myeloma at Ash
...alating Phase 1b clinical trial of Hsp90 inhibitor tanespimycin (KOS-953) in combination with bortezomib (Velcade(...n terms of convenience and ease of administration. tanespimycin is clearly an active and manageable agent and is d...ngful antitumor activity and tolerability with the tanespimycin plus bortezomib combination in multiple myeloma ac......rvival. Tanespimycin (KOS-953) is being tested in combination with bortezomib in patients with multiple myeloma in a registration program called TIME. tanespimycin is also being studied in HER2-positive metastatic breast cancer in combination with Herceptin, and as monotherapy in metastatic melanoma. Intravenous ...
Kosan Opens Registration Program for Lead Hsp90 Inhibitor, Tanespimycin, in Multiple Myeloma
... tanespimycin is Industry's First Hsp90 Inhibitor to Enter Regis...IME Registration Program Utilizes New, Proprietary tanespimycin Formulation HAYWARD...olling patients. This marks the opening of Kosan's tanespimycin in Myeloma Evaluation or "TIME" registration progr...Kosan Announces Data Presentations at Upcoming AACR Annual Meeting
... safety profile and Molecular of tanespimycin Therapeutics 13 (KOS-5: 953) -- ...lved in cancer cell growth and survival. Kosan's proprietary formulation of tanespimycin (KOS-953) is currently in Phase 1 and 2 clinical trials, primarily for mult...Tanespimycin in Biological Technology
Kosan Appoints Pamela S. Cohen, M.D., as Chief Medical Officer
...on targeting multiple pathways involved in cancer cell growth and survival. tanespimycin (KOS-953) is being tested in combination with Velcade(R) (bortezomib) in patients with multiple myeloma in a clinical program called TIME. tanespimycin is also being studied in HER2-positive metastatic breast cancer in combinat...Kosan Biosciences to Present at the Leerink Swann Solid Tumors Roundtable Conference
...on targeting multiple pathways involved in cancer cell growth and survival. tanespimycin (KOS-953) is being tested in combination with Velcade(R) (bortezomib) in patients with multiple myeloma in a clinical program called TIME. tanespimycin is also being studied in HER2-positive metastatic breast cancer in combinat...Kosan Announces May 1, 2008 Conference Call and Webcast of First Quarter 2008 Financial Results
...on targeting multiple pathways involved in cancer cell growth and survival. tanespimycin (KOS-953) is being tested in combination with Velcade(R) (bortezomib) in patients with multiple myeloma in a clinical program called TIME. tanespimycin is also being studied in HER2-positive metastatic breast cancer in combinat...Kosan Presents Preclinical Data on Novel Third-Generation Hsp90 Inhibitors at AACR
...on targeting multiple pathways involved in cancer cell growth and survival. tanespimycin (KOS-953) is being tested in combination with Velcade(R) (bortezomib) in patients with multiple myeloma in a clinical program called TIME. tanespimycin is also being studied in HER2-positive metastatic breast cancer in combinat...Kosan Restructures Workforce to Focus Resources on Lead Clinical Programs
...porting advancement of its lead clinical programs, tanespimycin in multiple myeloma and in metastatic breast cance...hways involved in cancer cell growth and survival. tanespimycin (KOS-953) is being tested in combination with Velc...ultiple myeloma in a clinical program called TIME. tanespimycin is also being studied in HER2-positive metastatic ...Kosan's Board of Directors Appoints Helen S. Kim as Chief Executive Officer
...on targeting multiple pathways involved in cancer cell growth and survival. tanespimycin (KOS-953) is being tested in combination with Velcade(R) (bortezomib) in patients with multiple myeloma in a clinical program called TIME. tanespimycin is also being studied in HER2-positive metastatic breast cancer in combinat...Kosan Biosciences to Present at the Cowen and Company 28th Annual Health Care Conference
...on targeting multiple pathways involved in cancer cell growth and survival. tanespimycin (KOS-953) is being tested in combination with bortezomib (Velcade(R)) in patients with multiple myeloma in a clinical program called TIME. tanespimycin is also being studied in HER2-positive metastatic breast cancer in combinat......on targeting multiple pathways involved in cancer cell growth and survival. tanespimycin (KOS-953) is being tested in combination with bortezomib (Velcade(R)) in patients with multiple myeloma in a clinical program called TIME. tanespimycin is also being studied in HER2-positive metastatic breast cancer in combinat...
Kosan Announces Senior Management Changes and Clinical Portfolio Priorities
...alue for the company in the near-term. -- The tanespimycin TIME registration program in multiple myeloma, ...myeloma in early 2009. -- Kosan plans to advance tanespimycin in metastatic breast cancer. To lay the groun...Kosan plans to commence enabling studies with tanespimycin as monotherapy and as combination therapy beg...Kosan Announces Fourth Quarter and Full Year 2007 Financial Results and 2008 Outlook
... top priorities in 2008 are the advancement of the tanespimycin TIME program in multiple myeloma and the tanespimycin metastatic breast cancer clinical program, and the...hways involved in cancer cell growth and survival. tanespimycin (KOS-953) is being tested in combination with bort...Other TagsOther Contents
AxiusDYNALINKOMNILINKPERRYEnTrustApeelACPElutraOptipressMultipetteDistrimanMaxipettorReflexioneValuator
(Date:5/19/2013)... California (PRWEB) May 19, 2013 Grinding ... than just losing sleep, or annoying your spouse. At ... report by CNY Central (“Snoring and Teeth Grinding Could ... type of teeth grinding can be hard to prevent. ... million Americans, and one of its symptoms is a ...
(Date:5/19/2013)... (PRWEB) May 19, 2013 According ... Market Analysis and Forecast (2013 – 2018): By ... Defense, Industrial)); Technology (CCD, CMOS, Contact IS, Infrared, ... of image sensor market was $8.00 billion in ... in 2018, at an estimated CAGR of 3.84% ...
(Date:5/19/2013)... 6Webs.com is the leader in reviews ... are considering an alarm system can do a comparison ... security system providers online at 6Webs.com. Just recently finishing ... home security system companies, 6Webs.com currently is announcing ... home security companies before ranking the home security system ...
(Date:5/19/2013)... These molecular diagnostics market reports ... Japan, Italy, Germany and France:, ... practice, as well as key economic, regulatory, demographic, ... during the next five years. , An ... test formats, detection methodologies, trends in testing automation ...
(Date:5/19/2013)... 19, 2013 The report “Feed Additives ... & Forecasts up to 2017” published by MarketsandMarkets, defines ... analysis and forecasting of the global volume and revenue ... driving and restraining factors for the global market with ... challenges. The market is segmented and revenue is forecasted ...
Breaking Medicine News(10 mins):Health News:Dr. Kanani, Woodland Hills Dentist: Dangers of Tooth Damage and Obstructive Sleep Disorder 2Health News:Dr. Kanani, Woodland Hills Dentist: Dangers of Tooth Damage and Obstructive Sleep Disorder 3Health News:Image Sensors Market to Reach $10.75 Billion by 2018 at a CAGR of 3.84% - New Report by MarketandMarkets 2Health News:Image Sensors Market to Reach $10.75 Billion by 2018 at a CAGR of 3.84% - New Report by MarketandMarkets 3Health News:Top Rated DIY Home Security System Companies Published by 6Webs.com 2Health News:Molecular Diagnostics Market - US, UK, Spain, Japan, Italy, Germany & France Analysis in New Research Report at ReportsnReports.com 2Health News:Molecular Diagnostics Market - US, UK, Spain, Japan, Italy, Germany & France Analysis in New Research Report at ReportsnReports.com 3Health News:Molecular Diagnostics Market - US, UK, Spain, Japan, Italy, Germany & France Analysis in New Research Report at ReportsnReports.com 4Health News:Feed Additives Market to Reach $19.5 Billion by 2017 at a CAGR of 3.8% - New Report by MarketandMarkets 2Health News:Feed Additives Market to Reach $19.5 Billion by 2017 at a CAGR of 3.8% - New Report by MarketandMarkets 3[0] Dr. Kanani, Woodland Hills Dentist: Dangers of Tooth Damage and Obstructive Sleep Disorder[0] Image Sensors Market to Reach $10.75 Billion by 2018 at a CAGR of 3.84% - New Report by MarketandMarkets[0] Top Rated DIY Home Security System Companies Published by 6Webs.com[0] Molecular Diagnostics Market - US, UK, Spain, Japan, Italy, Germany & France Analysis in New Research Report at ReportsnReports.com[0] Feed Additives Market to Reach $19.5 Billion by 2017 at a CAGR of 3.8% - New Report by MarketandMarkets
(Date:5/18/2013)... Bethesda, MD (May 19, 2013) The AGA Research ... Augustyn and Damian Augustyn Award in Digestive Cancer, which ... School of Medicine at the University of Pennsylvania, Philadelphia, ... Zeb1 in pancreas development, regeneration and cancer progression. , ... award in honor of two distinguished clinicians and AGA ...
(Date:5/18/2013)... presented today at Digestive Disease Week (DDW) explores new ... impact of coffee on autoimmune disease and palliative care ... has been associated with reduced risk of fibrosis, a ... of java each month also correlate with lower risk ... Mayo Clinic, Rochester, MN, linked coffee consumption with reduced ...
(Date:5/18/2013)... Research presented at Digestive Disease Week (DDW) explores ... and lifestyle. , Individuals suffering from Crohn,s ... fatigue and poor quality of life. These symptoms ... A randomized, double blind, placebo-controlled study found for ... to significant relief of these symptoms. , ...
Breaking Biology News(10 mins):AGA Research Foundation grant furthers digestive cancer research 2Coffee consumption associated with reduced risk of autoimmune liver disease 2Research examines new methods for managing digestive health 2Research examines new methods for managing digestive health 3| Copyright © 2003-2012 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |